company background image
2137

Brii Biosciences SEHK:2137 Stock Report

Last Price

HK$7.91

Market Cap

HK$5.7b

7D

-14.0%

1Y

-83.5%

Updated

28 Nov, 2022

Data

Company Financials +
2137 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

2137 Stock Overview

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases.

Brii Biosciences Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Brii Biosciences
Historical stock prices
Current Share PriceHK$7.91
52 Week HighHK$48.65
52 Week LowHK$4.70
Beta0
1 Month Change41.25%
3 Month Change2.20%
1 Year Change-83.47%
3 Year Changen/a
5 Year Changen/a
Change since IPO-65.53%

Recent News & Updates

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Sep 20
We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Recent updates

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Sep 20
We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Mar 24
We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Shareholder Returns

2137HK BiotechsHK Market
7D-14.0%-9.4%-0.2%
1Y-83.5%-52.0%-24.6%

Return vs Industry: 2137 underperformed the Hong Kong Biotechs industry which returned -52% over the past year.

Return vs Market: 2137 underperformed the Hong Kong Market which returned -24.6% over the past year.

Price Volatility

Is 2137's price volatile compared to industry and market?
2137 volatility
2137 Average Weekly Movement16.1%
Biotechs Industry Average Movement11.3%
Market Average Movement8.0%
10% most volatile stocks in HK Market15.0%
10% least volatile stocks in HK Market3.9%

Stable Share Price: 2137 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: 2137's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
2017123Zhi Honghttps://www.briibio.com

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria.

Brii Biosciences Limited Fundamentals Summary

How do Brii Biosciences's earnings and revenue compare to its market cap?
2137 fundamental statistics
Market CapHK$5.65b
Earnings (TTM)-HK$1.70b
Revenue (TTM)HK$81.50m

70.5x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2137 income statement (TTM)
RevenueCN¥74.77m
Cost of RevenueCN¥0
Gross ProfitCN¥74.77m
Other ExpensesCN¥1.63b
Earnings-CN¥1.56b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.14
Gross Margin100.00%
Net Profit Margin-2,084.15%
Debt/Equity Ratio0%

How did 2137 perform over the long term?

See historical performance and comparison